Patents by Inventor Alexander Glenn Godfrey

Alexander Glenn Godfrey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7405299
    Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Todd Vincent Decollo, Alexander Glenn Godfrey, Charles Raymond Heap, Chi-Hsin Richard King, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Yan Wang, Clive Gideon Diefenbacher, Thomas Albert Engler, Sushant Malhotra, Sreenivasa Reedy Mundla
  • Publication number: 20080146631
    Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl, R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a preoxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Application
    Filed: January 11, 2008
    Publication date: June 19, 2008
    Inventors: Dawn Alisa Brooks, Scott Eugene Conner, Samuel James Dominianni, Alexander Glenn Godfrey, Lynn Stacy Gossett, Christopher John Rito, Allie Edward Tripp, Alan M. Warshawsky, Leonard Larry Winneroski, Guoxin Zhu
  • Patent number: 7351728
    Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: April 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Dawn Alisa Brooks, Scott Eugene Conner, Samuel James Dominianni, Alexander Glenn Godfrey, Lynn Stacy Gossett, Christopher John Rito, Allie Edward Tripp, Alan M. Warshawsky, Leonard Larry Winneroski, Jr., Guoxin Zhu
  • Patent number: 7345070
    Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: March 18, 2008
    Assignee: Eli Lilly and Company
    Inventors: Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, James Ray McCarthy, Christopher John Rito, Leonard Larry Winneroski, Yanping Xu
  • Patent number: 7309702
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: December 18, 2007
    Assignees: Avera Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang, Jeffrey Forrester McKelvy
  • Patent number: 7176224
    Abstract: Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: February 13, 2007
    Assignee: Eli Lilly and Company
    Inventors: Robert J Ardecky, Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, Nathan Bryan Mantlo, James Ray McCarthy, Pierre Yves Michellys, Christopher John Rito, John S Tyhonas, Leonard Larry Winneroski, Yanping Xu
  • Patent number: 7087626
    Abstract: Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Todd Vincent DeCollo, Alexander Glenn Godfrey, Theodore Goodson, Jr., Hong-Yu Li, William Thomas McMillen, Shawn Christopher Miller, Jason Scott Sawyer, Edward C. R. Smith, Jonathan Michael Yingling
  • Patent number: 7001908
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: February 21, 2006
    Assignees: Avera Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Patent number: 6982278
    Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: January 3, 2006
    Assignee: Eli Lilly and Company
    Inventors: Dawn Alisa Brooks, Scott Eugene Conner, Samuel James Dominianni, Alexander Glenn Godfrey, Lynn Stacy Gossett, Christopher John Rit, Allie Edward Tripp, Alan M. Warshawsky, Leonard Larry Winneroski, Jr., Guoxin Zhu
  • Patent number: 6946579
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: September 20, 2005
    Assignee: Eli Lilly and Company
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Patent number: 6930120
    Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, James Ray McCarthy, Christopher John Rito, Leonard Larry Winneroski, Yanping Xu
  • Publication number: 20040138277
    Abstract: 1
    Type: Application
    Filed: July 29, 2003
    Publication date: July 15, 2004
    Inventors: Robert J Ardecky, Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, Nathan Bryan Mantlo, James Ray McCarthy, Pierre Yves Michellys, Christopher John Rito, John S Tyhonas, Leonard Larry Winneroski, Yanping Xu
  • Publication number: 20040106604
    Abstract: Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors. The disclosed invention relates to compounds of the structure (I) wherein (I) is a four, five, or six membered saturated ring and X is C, O or S.
    Type: Application
    Filed: November 6, 2003
    Publication date: June 3, 2004
    Inventors: Douglas Beight, Todd DeCollo, Alexander Glenn Godfrey, Theodore Goodson, Hong-Yu Li, William McMillen, Shawn Christopher Miller, Jason Sawyer, Edward C.R. Smith, Jonathan Michael Yingling
  • Publication number: 20040097590
    Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Application
    Filed: January 29, 2003
    Publication date: May 20, 2004
    Inventors: Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, James Ray McCarthy, Christopher John Rito, Leonard Larry Winneroski, Yanping Xu
  • Publication number: 20040049083
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: July 2, 2003
    Publication date: March 11, 2004
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Publication number: 20040044009
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: April 16, 2003
    Publication date: March 4, 2004
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Publication number: 20040024034
    Abstract: Compounds represented by the following (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
    Type: Application
    Filed: January 29, 2003
    Publication date: February 5, 2004
    Inventors: Dawn Alisa Brooks, Scott Eugene Conner, Samuel James Dominianni, Alexander Glenn Godfrey, Lynn Stacy Gossett, Christopher John Rito, Allie Edward Tripp, Alan M. Warshawsky, Leonard Larry Winneroski, Guoxin Zhu
  • Publication number: 20030153764
    Abstract: The present invention provides a process for preparing N-protected-4-substituted piperidines of formula (I) wherein Pg represents a suitable nitrogen protecting group; X represents a heterocycle, substituted heterocycle, substituted alkenyl or substituted aryl wherein the substituted heterocycle, substituted alkenyl or substituted aryl are substituted with from 1 to 3 suitable activating groups; and R1, R2, R3, R4, R5, R6, R7, and R8 each independently represent an alkyl, alkenyl, cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle, comprising treating a compound of formula (II) wherein the substituents are defined as above, with triethylsilane and trifluoroacetic acid.
    Type: Application
    Filed: May 28, 2002
    Publication date: August 14, 2003
    Inventors: Alexander Glenn Godfrey, Steven Wayne Pedersen
  • Publication number: 20020169170
    Abstract: A method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, comprising administering to a patient in need of such treatment a serotonin reuptake inhibitor in combination with an effective amount of a compound of the formula 1
    Type: Application
    Filed: December 18, 2001
    Publication date: November 14, 2002
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O' Toole, Yao-Chang Xu, Tony Yantao Zhang
  • Publication number: 20010003749
    Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
    Type: Application
    Filed: January 3, 2001
    Publication date: June 14, 2001
    Inventors: Alexander Glenn Godfrey, Daniel Timothy Kohlman, John Cunningham O'Toole, Yao-Chang Xu, Tony Yantao Zhang